Article | May 12, 2026

Avoiding Launch Delays With A Proactive Tech Transfer Strategy

pharma-manufacturing- GettyImages-2274021643

Commercial technology transfer is often treated as a final step, but in reality it is a critical phase where strategic decisions can determine whether a launch stays on track or slips. This piece reframes tech transfer as an active, collaborative process that must begin well before commercial scale. As timelines tighten and scrutiny increases, gaps in process understanding, regulatory flexibility, supplier readiness, or partner alignment can quickly become costly obstacles.

A commercially focused approach starts with designing processes for long‑term manufacturability, not just regulatory approval. Applying Quality by Design principles helps teams distinguish truly critical parameters from those that unnecessarily limit future operations. Equally important is recognizing that scale‑up is as much a supply chain exercise as a technical one, requiring early forecasting, supplier alignment, and contingency planning for long‑lead materials.

The article also highlights the importance of establishing CDMO partnerships early, before pressure mounts. When communication models, decision‑making frameworks, and risk tolerance are already aligned, teams are better equipped to navigate inevitable challenges. Together, these practices transform tech transfer from a reactive handoff into a deliberate strategy for reliable, on‑time commercialization.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online